SCHEMBL496194

SCHEMBL496194

Cc1cc(C#N)c(N[C@H]2CCCC[C@@H]2NC(=O)O)cc1Cl

nearest known ligand 0.40

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CHEK1 O14757 3/20 0.40
RPS6KA3 P51812 3/20 0.40
SRPK1 Q96SB4 3/20 0.40
FER P16591 5/20 0.37
MAP4K4 O95819 2/20 0.36
RET P07949 2/20 0.36
FLT4 P35916 2/20 0.36
CLK2 P49760 2/20 0.36
GSK3B P49841 2/20 0.36
IRAK1 P51617 2/20 0.36
BRSK1 Q8TDC3 2/20 0.36
MAP4K5 Q9Y4K4 2/20 0.36
IKBKB O14920 1/20 0.36
AURKA O14965 1/20 0.36
DCLK1 O15075 1/20 0.36
RPS6KA5 O75582 1/20 0.36
PRKD3 O94806 1/20 0.36
PHKG2 P15735 1/20 0.36
CDK2 P24941 1/20 0.36
MAPKAPK2 P49137 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4368419 0.91 FER (0.36) CHEK1RPS6KA3SRPK1FERACP1
SCHEMBL496442 0.89 FER (0.34) CHEK1RPS6KA3SRPK1FERACP1
SCHEMBL496253 0.81 ALDH1A1 (0.42) FERHTTRAB9AALDH1A1L3MBTL1
SCHEMBL4367918 0.81 ALDH1A1 (0.42) FERHTTRAB9AALDH1A1L3MBTL1
SCHEMBL496358 0.81 CHEK1 (0.36) CHEK1RPS6KA3SRPK1MAP4K4RET
SCHEMBL496119 0.81 FER (0.39) CHEK1RPS6KA3SRPK1FERAR
SCHEMBL16147403 0.76 FGFR4 (0.39) CHEK1RPS6KA3SRPK1FERAR
SCHEMBL2712647 0.76 FER (0.35) FERACP1PTPN7PTPN12PTPN22
SCHEMBL9106184 0.76 FER (0.35) FERACP1PTPN7PTPN12PTPN22
SCHEMBL495955 0.74 MEN1 (0.33) CHEK1RPS6KA3SRPK1ALDH1A1AR

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1955697-B1 2-AMINOBENZAMIDE DERIVATIVES AS VANILLOID RECEPTOR 1 (VR1) INHIBITORS USEFUL FOR THE TREATMENT OF PAIN OR BLADDER FUNCTION DISORDER ASTELLAS PHARMA INC (JP) 2012-05-02 EP disclosed
US-8106190-B2 2-aminobenzamide derivatives ASTELLAS PHARMA INC. (JP) 2012-01-31 US disclosed
US-20090233900-A1 2-AMINOBENZAMIDE DERIVATIVE ASTELLAS PHARMA INC. (JP) 2009-09-17 US disclosed
EP-1955697-A1 2-AMINOBENZAMIDE DERIVATIVE Astellas Pharma Inc. (JP) 2008-08-13 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090233900-A1 2-AMINOBENZAMIDE DERIVATIVE TRPV1, TRPV2, TRPV5 CHEK1 3364/4885RPS6KA3 4432/4885SRPK1 4220/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.